Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Recent years have seen major advances in elucidating the complexity of chromatin and its role as an epigenetic regulator of gene expression in eukaryotes. We now have a basic understanding of chromatin control and the enzymatic modifications that impart diverse regulatory cues to the functional activity of the genome. Most importantly, although research into chromatin has uncovered fascinating insights into the control of gene expression, it has also generated a large body of information that is being harnessed to develop new therapeutic modalities for treating cancer. Here, we discuss recent advances that support the contention that future generations of chromatin-modulating drugs will provide a significant group of new, mechanism-based therapeutics for cancer.

Original publication

DOI

10.1016/S1359-6446(05)03691-3

Type

Journal article

Journal

Drug Discov Today

Publication Date

02/2006

Volume

11

Pages

97 - 109

Keywords

Antineoplastic Agents, Chromatin, Drug Design, Gene Expression Regulation, Neoplastic, Histone Acetyltransferases, Histone Deacetylase Inhibitors, Histone Deacetylases, Humans, Methyltransferases, Neoplasms, Phosphorylation